Status:
COMPLETED
Tobramycin Tear Concentrations
Lead Sponsor:
Alcon Research
Conditions:
Dry Eye
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
To evaluate the Tobramycin tear concentration values of TOBRADEX® Ophthalmic Suspension, Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension versus TOBREX® Ophthalmic Solution in normal volunt...
Eligibility Criteria
Inclusion
- Inclusion:
- Visual Acuity (VA) of 0.6 logMAR or better
- Tear meniscus height of ≥ 0.3mm at Visit 1.
- No concomitant topical ocular medications, including artificial tears, during the study period
- Exclusion
- ocular hypertension, iritis or uveitis, glaucoma
- ocular surgery, intraocular surgery or ocular laser procedures in either eye within the past six months
- epithelial herpes simplex (dendritic keratitis); Vaccinia, active or recent varicella viral disease of the cornea and/or conjunctiva; ocular Rosacea; Mycobacterial infection of the eye; and / or fungal disease of the eye
- lacrimal duct obstruction, dry eye, ocular allergies.
- contact lens within 7 days of Visit 1.
- ocular medications within 14 days of Visit 1.
Exclusion
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT00695435
Start Date
June 1 2008
Last Update
March 2 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Contact Alcon Call Center For Trial Locations
Fort Worth, Texas, United States, 76134